ICON plc
ICON provides outsourced development and commercialization services globally.
The company specializes in clinical development programs from compound selection to Phase I-IV studies.
Services include clinical trial management, consulting, contract staffing, data solutions, and site access.
Additionally, ICON offers laboratory services, including bionanalytical and central lab services.
The company also provides adaptive trials, cardiac safety solutions, and real-world intelligence.
ICON serves pharmaceutical, biotechnology, medical device industries, government, and public health organizations.
Headquartered in Dublin, Ireland since 1990.
Overview
Strengths
- Asset-light, cash-generative model: capital expenditure takes only 1.9% of revenue and free cash flow was positive in each of the last 6 years.
- Resilient profitability: operating margin stayed between 11% and 15% in each of the last 6 years.
- Valued below its Diagnostics & Research peers: P/FCF 17.9x vs. a median of 24.7x.
- Consistent growth: revenue has compounded at 24.2% a year over 5 years, rising every year.
- Shareholder-friendly capital allocation: the share count has shrunk by 2.1% a year over the last three years through buybacks.
- Cheaper than its own history: P/FCF 17.9x vs. a historical average of 24.7x and EV/EBITDA 13.1x vs. a historical average of 18.5x.
Weaknesses
- Heavy interest burden: interest expense absorbs 43% of operating profit.
- Our discounted cash flow target price (146.18 USD) is 28% below the current price.
- Valued at a premium to its Diagnostics & Research peers: P/E 67.3x vs. a median of 31.4x.
Key Financial Data